Strain-Dependent Restriction of Human Cytomegalovirus by Zinc Finger Antiviral Proteins.
cytomegalovirus
herpesviruses
interferons
zinc finger antiviral protein
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
30 03 2023
30 03 2023
Historique:
medline:
3
4
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
Cellular antiviral factors that recognize viral nucleic acid can inhibit virus replication. These include the zinc finger antiviral protein (ZAP), which recognizes high CpG dinucleotide content in viral RNA. Here, we investigated the ability of ZAP to inhibit the replication of human cytomegalovirus (HCMV). Depletion of ZAP or its cofactor KHNYN increased the titer of the high-passage HCMV strain AD169 but had little effect on the titer of the low-passage strain Merlin. We found no obvious difference in expression of several viral proteins between AD169 and Merlin in ZAP knockdown cells, but observed a larger increase in infectious virus in AD169 compared to Merlin in the absence of ZAP, suggesting that ZAP inhibited events late in AD169 replication. In addition, there was no clear difference in the CpG abundance of AD169 and Merlin RNAs, indicating that genomic content of the two virus strains was unlikely to be responsible for differences in their sensitivity to ZAP. Instead, we observed less ZAP expression in Merlin-infected cells late in replication compared to AD169-infected cells, which may be related to different abilities of the two virus strains to regulate interferon signaling. Therefore, there are strain-dependent differences in the sensitivity of HCMV to ZAP, and the ability of low-passage HCMV strain Merlin to evade inhibition by ZAP is likely related to its ability to regulate interferon signaling, not the CpG content of RNAs produced from its genome.
Identifiants
pubmed: 36916924
doi: 10.1128/jvi.01846-22
pmc: PMC10062169
mid: EMS170712
doi:
Substances chimiques
Neurofibromin 2
0
RNA-Binding Proteins
0
Antiviral Agents
0
Interferon Type I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0184622Subventions
Organisme : Medical Research Council
ID : MR/S000844/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W018519/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S00971X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098049
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W025647/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/3
Pays : United Kingdom
Références
J Virol. 2003 Nov;77(21):11555-62
pubmed: 14557641
Cell. 2019 Jun 13;177(7):1797-1813.e18
pubmed: 31104839
Cell. 2014 Jun 5;157(6):1460-1472
pubmed: 24906157
J Gen Virol. 2008 Feb;89(Pt 2):359-368
pubmed: 18198366
Virol J. 2015 Dec 01;12:203
pubmed: 26625984
Cell Rep. 2022 Mar 8;38(10):110469
pubmed: 35263605
Science. 2002 Sep 6;297(5587):1703-6
pubmed: 12215647
J Virol. 2007 Mar;81(5):2391-400
pubmed: 17182693
Antiviral Res. 2015 Nov;123:50-61
pubmed: 26343012
Nat Microbiol. 2022 Oct;7(10):1558-1567
pubmed: 36075961
J Virol. 1998 Apr;72(4):2697-707
pubmed: 9525587
Nat Immunol. 2011 Jan;12(1):37-44
pubmed: 21102435
PLoS Genet. 2008 Jan;4(1):e21
pubmed: 18225958
J Biol Chem. 2010 Feb 26;285(9):6080-90
pubmed: 20048147
Nat Immunol. 2019 Dec;20(12):1610-1620
pubmed: 31740798
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11085-90
pubmed: 23776219
J Gen Virol. 2004 May;85(Pt 5):1301-1312
pubmed: 15105547
Nature. 2017 Oct 5;550(7674):124-127
pubmed: 28953888
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15834-9
pubmed: 21876179
BMC Genomics. 2018 Aug 2;19(1):577
pubmed: 30068288
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35105802
PLoS Pathog. 2017 Jan 6;13(1):e1006145
pubmed: 28060952
Nat Struct Mol Biol. 2012 Mar 11;19(4):430-5
pubmed: 22407013
J Gen Virol. 2009 Oct;90(Pt 10):2375-2380
pubmed: 19553388
J Clin Invest. 2010 Sep;120(9):3191-208
pubmed: 20679731
J Virol. 2013 Oct;87(19):10489-500
pubmed: 23885075
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):151-6
pubmed: 17185417
Viruses. 2021 Sep 17;13(9):
pubmed: 34578438
J Virol. 2013 Mar;87(5):2735-43
pubmed: 23255809
PLoS Pathog. 2020 Sep 4;16(9):e1008844
pubmed: 32886716
PLoS Biol. 2021 Apr 19;19(4):e3001201
pubmed: 33872300
Nucleic Acids Res. 2019 Sep 5;47(15):8061-8083
pubmed: 31276592
mBio. 2021 May 4;12(3):
pubmed: 33947766
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24303-24309
pubmed: 31719195
PLoS Pathog. 2020 Aug 31;16(8):e1008845
pubmed: 32866210
J Virol. 2019 Aug 28;93(18):
pubmed: 31118263
J Virol. 2017 Apr 13;91(9):
pubmed: 28202764
J Virol. 2004 Oct;78(19):10360-9
pubmed: 15367602
mBio. 2020 Jan 14;11(1):
pubmed: 31937644
Med Microbiol Immunol. 2015 Jun;204(3):273-84
pubmed: 25894764
PLoS Pathog. 2021 Apr 26;17(4):e1009545
pubmed: 33901262
Elife. 2019 Jul 09;8:
pubmed: 31284899
PLoS Pathog. 2018 Jul 17;14(7):e1007166
pubmed: 30016363
EMBO J. 2012 Nov 5;31(21):4236-46
pubmed: 23023399
BMC Genomics. 2013 Sep 10;14:610
pubmed: 24020411
J Virol. 1994 May;68(5):2889-97
pubmed: 8151759
PLoS Pathog. 2013;9(7):e1003494
pubmed: 23853601
Virol J. 2021 Jun 3;18(1):112
pubmed: 34082757
Elife. 2017 Sep 29;6:
pubmed: 28960178
Cell Rep. 2020 Jan 7;30(1):46-52.e4
pubmed: 31914396
Cell Host Microbe. 2018 Sep 12;24(3):447-460.e11
pubmed: 30122656
J Virol. 2020 Feb 28;94(6):
pubmed: 31748389
Annu Rev Virol. 2021 Sep 29;8(1):265-283
pubmed: 34129371